Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report

2021; SAGE Publishing; Volume: 30; Linguagem: Inglês

10.1177/09636897211021008

ISSN

1555-3892

Autores

Alexandra Cristina Senegaglia, Cármen Lúcia Kuniyoshi Rebelatto, Cláudio Luciano Franck, Juliana Souza Lima, Lidiane Maria Boldrini Leite, Débora Regina Daga, Cleverson Alex Leitão, Patrícia Shigunov, Ana Paula de Azambuja, Elisa Bana, Daniela Boscaro Marsaro, Bruna Schaidt, Andressa Micosky, Valderez Ravaglio Jamur, Yara Carolina Schluga, Isadora May Vaz, Lisandro Ribeiro, Alejandro Correa, e Paulo Roberto Slud Brofman,

Tópico(s)

Long-Term Effects of COVID-19

Resumo

The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease's symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O

Referência(s)